KROS Q2 2024 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37,000

Gross Profit

$37,000100.0% margin

Operating Income

-$50M-136321.6% margin

Net Income

-$45M-122316.2% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

-55.4%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$455M

Total Liabilities

$34M

Stockholders' Equity

$421M

Cash & Equivalents

$406M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37,000	$0	—
Gross Profit	$37,000	$0	—
Operating Income	-$50M	-$41M	-22.0%
Net Income	-$45M	-$38M	-20.7%

Revenue Segments

Service, Other

$37,000100%